U.S., April 24 -- ClinicalTrials.gov registry received information related to the study (NCT07548671) titled 'Enarodustat + CsA vs CsA in Newly Diagnosed TD-NSAA' on April 16.
Brief Summary: This study aimed to compare the efficacy and safety of enarodustat combined with cyclosporine versus cyclosporine monotherapy in the treatment of newly-diagnosed tansfusion-dependent non-severe aplastic anemia (TD-NSAA).
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
Transfusion-dependent Non-severe Aplastic Anemia
Intervention:
DRUG: Enarodustat
Enarodustat 8mg qd
DRUG: Cyclosporine (CsA)
CsA 3-5mg/kg/d, trough concentration 100-200ng/ml
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Peking Union Medical College Hospit...